` IGMS (IGM Biosciences Inc) vs S&P 500 Comparison - Alpha Spread

IGMS
vs
S&P 500

Over the past 12 months, IGMS has underperformed S&P 500, delivering a return of -85% compared to the S&P 500's 12% growth.

Stocks Performance
IGMS vs S&P 500

Loading

Performance Gap
IGMS vs S&P 500

Loading
IGMS
S&P 500
Difference

Performance By Year
IGMS vs S&P 500

Loading
IGMS
S&P 500
Add Stock

Competitors Performance
IGM Biosciences Inc vs Peers

S&P 500
IGMS
ABBV
AMGN
GILD
VRTX
Add Stock

IGM Biosciences Inc
Glance View

Market Cap
74m USD
Industry
Biotechnology

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. The company is headquartered in Mountain View, California and currently employs 192 full-time employees. The company went IPO on 2019-09-18. The company has developed an IgM antibody technology platform that is particularly well suited for developing T cell engagers, receptor cross-linking agonists and targeted cytokines. Its lead product candidate, IGM-2323, a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins, is in an ongoing Phase I clinical trial for the treatment of relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL) patients. Its second product candidate, IGM-8444, is an IgM antibody targeting Death Receptor 5 (DR5) proteins, which is for the treatment of patients with solid and hematologic malignancies. The Company’s pipeline also includes IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.

IGMS Intrinsic Value
1.68 USD
Undervaluation 26%
Intrinsic Value
Price
Back to Top